Geneva Partners’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-688
| Closed | -$222K | – | 73 |
|
|
2024
Q3 | $222K | Hold |
688
| – | – | 0.1% | 68 |
|
|
2024
Q2 | $215K | Buy |
+688
| New | +$202K | 0.09% | 65 |
|
|
2024
Q1 | – | Sell |
-793
| Closed | -$228K | – | 69 |
|
|
2023
Q4 | $228K | Buy |
793
+20
| +3% | +$5.45K | 0.13% | 69 |
|
|
2023
Q3 | $208K | Sell |
773
-335
| -30% | -$83.6K | 0.14% | 61 |
|
|
2023
Q2 | $246K | Sell |
1,108
-11,372
| -91% | -$2.64M | 0.16% | 69 |
|
|
2023
Q1 | $3.02M | Sell |
12,480
-1,240
| -9% | -$304K | 2.58% | 17 |
|
|
2022
Q4 | $3.6M | Buy |
13,720
+11,675
| +571% | +$3.13M | 3.4% | 11 |
|
|
2022
Q3 | $461K | Sell |
2,045
-10
| -0.5% | -$2.42K | 0.53% | 43 |
|
|
2022
Q2 | $500K | Hold |
2,055
| – | – | 0.49% | 40 |
|
|
2022
Q1 | $497K | Sell |
2,055
-10
| -0.5% | -$2.3K | 0.31% | 57 |
|
|
2021
Q4 | $465K | Sell |
2,065
-400
| -16% | -$84.4K | 0.22% | 69 |
|
|
2021
Q3 | $524K | Hold |
2,465
| – | – | 0.25% | 64 |
|
|
2021
Q2 | $601K | Sell |
2,465
-1,080
| -30% | -$266K | 0.28% | 67 |
|
|
2021
Q1 | $882K | Sell |
3,545
-335
| -9% | -$79.9K | 0.46% | 48 |
|
|
2020
Q4 | $892K | Sell |
3,880
-8,215
| -68% | -$1.89M | 0.47% | 52 |
|
|
2020
Q3 | $3.07M | Buy |
12,095
+445
| +4% | +$110K | 1.88% | 22 |
|
|
2020
Q2 | $2.75M | Buy |
11,650
+5,865
| +101% | +$1.34M | 1.93% | 21 |
|
|
2020
Q1 | $1.17M | Sell |
5,785
-265
| -4% | -$57.9K | 1.67% | 22 |
|
|
2019
Q4 | $1.46M | Sell |
6,050
-250
| -4% | -$55.1K | 1.01% | 34 |
|
|
2019
Q3 | $1.22M | Sell |
6,300
-1,725
| -21% | -$331K | 0.95% | 37 |
|
|
2019
Q2 | $1.48M | Sell |
8,025
-746
| -9% | -$134K | 1.19% | 30 |
|
|
2019
Q1 | $1.67M | Sell |
8,771
-1,175
| -12% | -$224K | 1.42% | 30 |
|
|
2018
Q4 | $1.84M | Buy |
9,946
+510
| +5% | +$99.5K | 2.13% | 19 |
|
|
2018
Q3 | $1.96M | Buy |
9,436
+635
| +7% | +$125K | 1.5% | 27 |
|
|
2018
Q2 | $1.63M | Sell |
8,801
-84
| -0.9% | -$14.9K | 1.29% | 27 |
|
|
2018
Q1 | $1.51M | Buy |
8,885
+78
| +0.9% | +$14.3K | 1.25% | 28 |
|
|
2017
Q4 | $1.53M | Sell |
8,807
-87
| -1% | -$15.4K | 1.15% | 30 |
|
|
2017
Q3 | $1.66M | Buy |
+8,894
| New | +$1.58M | 1.31% | 30 |
|
|
2016
Q2 | $1.56M | Buy |
+9,044
| New | +$1.41M | 1.4% | 31 |
|
Other funds holding AMGN
Geneva Partners's AMGN Position: Q4 2024 in Review
Geneva Partners sold out of Amgen (AMGN) in Q4 2024, closing a stake of 688 shares — an estimated $222K sold.
Geneva Partners first reported a position in AMGN in Q2 2016 and held it in 29 quarters. The position peaked at $3.6M in Q4 2022. 2,855 funds tracked by Wall St. Rank hold AMGN as of Q4 2024.
- Geneva Partners reported no remaining Amgen position as of Q4 2024 after selling out during the quarter.
- Geneva Partners sold 688 Amgen shares in Q4 2024, an estimated $222K.
- Geneva Partners first reported a position in Amgen in Q2 2016 and held it in 29 quarters.
- Geneva Partners's Amgen position peaked at $3.6M in Q4 2022.
- 2,855 funds tracked by Wall St. Rank held Amgen as of Q4 2024.
Based on Geneva Partners's 13F filing for Q4 2024, filed 27 Jan 2025.